MDI inks deal with Mylan Philippines

Metro Drug Inc (MDI) has entered into a new strategic partnership with Mylan Inc. for the promotion, selling, and distribution of antipsychotic drug Leponex and labour stimulation drug Syntocinon in the Philippines.

A global healthcare company, Mylan is the second-largest generic and speciality pharmaceutical company in the world with a diverse portfolio spanning more than 7,500 products. Ester Tacanay, Country Manager of Mylan Philippines, says, “We have known MDI for over a decade. Their strong expertise and wide reach, as well as responsive leadership and operating teams, are the main factors in our decision to partner with them”.

Jannette Jakosalem, Chief Executive MDI, added, “Mylan is MDI’s first commercialisation client and we are very grateful for the trust and confidence from the Mylan team. True to MDI’s promise of “Partnering Made Easy”, we stand by our commitment of delivering and surpassing client expectations to make healthcare more accessible in the Philippines.”